Administration of Monoclonal Antibodies for COVID Positive Patients

Situation: Approved medication for administration in patients with confirmed COVID-19 infection

Background: Health Canada approved the administration of casirivimab/imdevimab and sotrovimab in patient with confirmed COVID-19 infections.

Patient Criteria:

Patients must meet all of the following criteria,

- No previous history of COVID-19 infection
- Have not received two vaccinations i.e. are not fully vaccinated
- Are within 7 days of symptom onset (mild illness) or less than 9 days from symptom onset (moderate to critical illness)
- Have evidence of COVID-19 infection based on SARS-CoV2 PCR testing
- Have at least one of the following risk factors:
    - ✓ Greater than 50 years of age
    - ✓ Obesity
    - ✓ Cardiovascular disease (including hypertension)
    - ✓ Chronic lung disease (including asthma)
    - ✓ Chronic kidney disease
    - ✓ Chronic liver disease
    - ✓ Chronic metabolic disease (including diabetes)
    - ✓ Immunosuppression i.e. are receiving immunosuppressants
    - ✓ First Nations, Inuit or Metis

Drug Administration:

- Administration must be approved by Infectious Disease (ID) physician (ED MD will refer to ID)
- Patient may require rapid in-house NP swab for COVID-19 (to be approved by ID)
- Monitor vital signs to be completed at intervals of:
    - ✓ Start of the infusion
    - ✓ After 30 minutes
    - ✓ At the end (60 minutes)
    - ✓ Sixty minutes post infusion
- Monitor patient closely for infusion-related reactions

Drug Availability:

- Sotrovimab (for outpatients) are available in Orange zone ADU
- Casirivimab/imdevimab (for inpatients) doses will come prepared/pre-mixed from pharmacy
    - Remaining doses can be stored in the ED fridge for up to 36 hours

How to Administer:

- Administered intravenously using,
    - Alaris pump (refer to Alaris ED profile for mixing and administration instructions)
    - 0.2 inline micron filter
    - Over 1 hour
    - Flush tubing with NS after infusion completion to ensure full dose is administered
- Monitor for potential signs and symptoms of an infusion-related reaction including,
    - Fever or chills
    - Dyspnea
    - Hypoxia
    - Fatigue or weakness
    - Arrhythmia (e.g. atrial fibrillation, tachycardia, bradycardia)
    - Chest pain or discomfort
    - Altered mental status
    - Nausea
    - Headache
    - Bronchospasm
    - Hypotension or hypertension
    - Angioedema
    - Throat irritation
    - Rash (urticarial, pruritus)
    - Myalgia
    - Vasovagal reactions (e.g. pre-syncope or syncope)
    - Dizziness
    - Diaphoresis
- If the patient has any signs or symptoms of an infusion related reaction, STOP infusion and contact MRP